US OptionsDetailed Quotes

VERV240517P22500

Watchlist

5.40
0.000.00%

15min DelayClose Feb 28 11:34 ET

0.00High0.00Low

Verve Therapeutics Stock Discussion

frankinglily

May 14 16:38

How does the biotech ecosystem support advancements in personalized medicine & genomics?
• Editing Genes | $CRISPR Therapeutics(CRSP.US)$ , $Intellia Therapeutics(NTLA.US)$ , $Beam Therapeutics(BEAM.US)$ , $Verve Therapeutics(VERV.US)$ , $Editas Medicine(EDIT.US)$
• Creating Therapies | $Prime Medicine(PRME.US)$ , $Sana Biotechnology(SANA.US)$
• Building DNA | $Twist Bioscience(TWST.US)$ , $Ginkgo Bioworks(DNA.US)$ , $Pacific Biosciences of California(PACB.US)$ , $Illumina(ILMN.US)$
• Dis...

ClydePeternuts

May 14 15:16

Cathie Wood's Ark Invest Buys $18M In Shopify Stock Amid Price Dip, Sells Shares In Bitcoin Bull Jack Dorsey's Block Inc

On Monday, Cathie Wood’ s Ark Invest made some significant trades, the most notable being the purchase of $Shopify(SHOP.US)$ and the sale od $Block(SQ.US)$
The Shopify Trade
$ARK Fintech Innovation ETF(ARKF.US)$ $ARK Innovation ETF(ARKK.US)$ and $ARK Next Generation Internet ETF(ARKW.US)$ Purchased a total of 313,¢3 shares of Shopify on Monday. This move came after the company ...

Trytosaveabit

May 7 19:20

Update

$Verve Therapeutics(VERV.US)$ Verve Therapeutics Announces Dosing Of First Patient In Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

y f ii

Apr 2 22:23

$Verve Therapeutics(VERV.US)$ 6

Trytosaveabit

Apr 2 19:13

Read the whole PR! But reason for fall

$Verve Therapeutics(VERV.US)$ However, the sixth participant treated in the 0.45 mg/kg cohort experienced a Grade 3 drug-induced transient increase in serum alanine aminotransferase (ALT) as well as a serious adverse event of Grade 3 drug-induced thrombocytopenia within the first four days after dosing. The participant did not experience any bleeding or other symptoms related to the laboratory abnormalities, and the abnormalities resolved fully within a few ...

Moomoo AI

Mar 3 21:23

Analysts are optimistic about Verve Therapeutics, predicting reduced losses this year, indicating a move towards profitability. Despite expected slower revenue growth, it's still anticipated to outpace the industry. However, concerns like dilutive stock issuance over the past year persist.

Rainbows and Unicorns: Verve Therapeutics, Inc. (NASDAQ:VERV) Analysts Just Became A Lot More Optimistic

TheMetaHodler

Dec 30, 2023 01:38

$Verve Therapeutics(VERV.US)$ Loaded on insider buying!

TheMetaHodler

Dec 14, 2023 03:36

$Verve Therapeutics(VERV.US)$ Google is buying!

Trytosaveabit

Dec 6, 2023 19:56

Insider buy

$Verve Therapeutics(VERV.US)$ • Krishna Yeshwant, managing partner at Google Ventures and a director at Verve Therapeutics (NASDAQ:VERV), has acquired $18M in Verve common stock.
• In a transaction dated Dec 01, 2023, Yeshwant bought 1.8M shares of Verve's common stock at a price of $10 each.

STD0313

Nov 16, 2023 01:17

$Verve Therapeutics(VERV.US)$ still 400k shorts available on low volume. Could make another entry. Let the MMs lead on this one. They will decide soon enough

No comment yet